Notícias e Atividades da Dyadic Applied BioSolutions

Dyadic Applied BioSolutions é uma empresa listada sob o símbolo DYAI (US).

Veja o organograma con seus 11 executivos principais

Biografias mais buscadas da Dyadic Applied BioSolutions

• Mark Emalfarb, Chief Executive Officer and President
• Patrick Lucy, Chairman of the Board
• Seth Herbst, Director

Criar um alerta
para seguir os movimentos de executivos da Dyadic Applied BioSolutions.

Dyadic Applied BioSolutions possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Dyadic Applied BioSolutions

• RSS Feed of Press Releases for DYAIDyadic to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018Dyadic Announces Analyst Coverage Initiated by Zacks Small-Cap ResearchDyadic International to Present Thursday October 4, 2018 at 2:30
• Press Releases | Dyadic International, Inc :Dyadic International, Inc
• Dyadic International Improves Monoclonal Antibody (mAb) Productivity Utilizing C1 Gene Expression Platform to Manufacture Biologics | Dyadic International, Inc :Dyadic International, Inc

Redes sociais sobre Dyadic Applied BioSolutions

• Dyadic Applied BioSolutions na Wikipedia, Google News e Yahoo Finance
• Dyadic Applied BioSolutions na LinkedIn, X (Twitter) e YouTube